THE Therapeutic Goods Administration (TGA) has registered the first and only oromucosal cannabinoid treatment for prescription (Schedule 8) in Australia for the treatment of moderate and severe spasticity due to multiple sclerosis (MS).
The TGA nod for Sativex (nabiximols) from GW Pharma but sponsored by Emerge Health, brings to 30 the number of countries in which the product is registered.
Dr John Parratt, leading Sydney neurologist, based at Royal North Shore Hospital, welcomed the availability of Sativex in Australia saying, "Spasticity as a symptom due to MS has a major impact on patients and carers' lives so anything that can ease that burden is definitely useful to have as part of the treatment options".
More than 1,500 patients have been treated with Sativex in the clinical studies program to date.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Nov 17